PSP
JAZZ icon

Principal Street Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Principal Street Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,990
Closed -$211K – 322
2025
Q2 		$211K Buy
+1,990
New +$216K 0.02% 351

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Street Partners's JAZZ Position: Q3 2025 in Review

Principal Street Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 1,990 shares — an estimated $211K sold.

Principal Street Partners first reported a position in JAZZ in Q2 2025 and held it in 1 quarter. The position peaked at $211K in Q2 2025. 503 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

  • Principal Street Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Principal Street Partners sold 1,990 Jazz Pharmaceuticals shares in Q3 2025, an estimated $211K.
  • Principal Street Partners first reported a position in Jazz Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Principal Street Partners's Jazz Pharmaceuticals position peaked at $211K in Q2 2025.
  • 503 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on Principal Street Partners's 13F filing for Q3 2025, filed 14 Nov 2025.